MedTrace Logo

Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix

NCT05197881 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 125

Last updated 2025-09-23

No results posted yet for this study

Summary

This is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for locally advanced cervical cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT). The timepoint for this assessment will be at week 5 of external beam radiotherapy (EBRT) and will use the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Conditions

  • Cervical Cancer by FIGO Stage 2018

Interventions

DEVICE

Varian Ethos Adaptive Radiation Therapy

Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.

Sponsors & Collaborators

  • Varian, a Siemens Healthineers Company

    lead INDUSTRY

Principal Investigators

  • Jyoti Mayadev, MD · University of California, San Diego

  • Xenia Ray, PhD · University of California, San Diego

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-03
Primary Completion
2028-09-30
Completion
2030-09-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05197881 on ClinicalTrials.gov